Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ARUP Labs, UH Case Medical Center Sign Distribution Agreement for Novel HIV Test

Published: Monday, July 21, 2014
Last Updated: Monday, July 21, 2014
Bookmark and Share
DEEPGEN™HIV monitors the success of anti-HIV treatment by determining drug resistance and the ability of the virus to infect different cells based on deep genetic sequencing.

University Hospitals Case Medical Center has signed an agreement with ARUP Laboratories, a major national clinical reference laboratory that offers an extensive menu of highly complex and unique medical tests to hospitals, medical schools, and other nonprofit and commercial organizations throughout the United States. 

Under the agreement, ARUP will include in its menu of tests an HIV diagnostic test invented at University Hospitals’ Translational Laboratory by Miguel Quinones-Mateu, PhD, scientific director at the UH lab and assistant professor at the Department of Pathology, Case Western Reserve University School of Medicine. 

The novel test, DEEPGEN™HIV, monitors the success of anti-HIV treatment by determining drug resistance and the ability of the virus to infect different cells based on deep genetic sequencing. ARUP, a nonprofit enterprise of the University of Utah, will include DEEPGEN in its menu of tests and will nationally market the assay. Clinical samples will then be referred to UH Translational Laboratory (UHTL, www.uhtl.org) in Cleveland from all 50 states. 

DEEPGEN™HIV provides a sensitive platform for HIV physicians and researchers, both in the academia and industry. The assay allows the detection of minority variants at frequencies unimaginable with current HIV genotypic tests based on standard (Sanger) sequencing. 

“Although the clinical relevance of these minority members of the viral population is still under debate, it is reasonable to assume that the earlier these mutant viruses are detected, the sooner the proper strategy can be defined to control their growth,” said Dr. Quiñones-Mateu. “DEEPGEN™HIV is now the primary HIV genotyping assay used by HIV physicians at the Case Western Reserve University/University Hospitals AIDS Clinical Trials Unit, and we have been analyzing clinical specimens from other institutions around the region. This agreement with ARUP will expedite the use of this innovative and highly sensitive assay nationwide, which will allow us to enhance the care and treatment of HIV-infected individuals across the country.” 

“I am excited about our relationship with ARUP, as it appears to be a natural synergy that we both may leverage to expand the quality of diagnostic testing and care provided to patients with HIV nationally,” said Ronald E. Dziedzicki, chief operating officer at UH Case Medical Center. 

“Our relationship with UH Case Medical Center enables ARUP to offer this innovative test to our clients for the management of patients with HIV,” said Jerry Hossong, MD, DDS, ARUP’s chief medical officer and director of laboratories. “We are very pleased to include this test as part of our comprehensive menu of services.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
RNA Suppresses Inflammation
Researchers identify a long noncoding RNA that regulates innate immunity.
Competition to Decipher RNA-Cancer Link
DREAM challenge aims to find the best algorithms for detecting abnormal RNA molecules in cancer cells.
Red Hair Gene Increases Cancer Mutations
Red hair gene variant drives up skin cancer mutations equivalent to that expected from 21 years of sun exposure.
Type 2 Diabetes Genetics Revealed
The largest study of its kind into type 2 diabetes has produced the most detailed picture to date of the genetics underlying the condition.
Blood Cancer Could be Prevented Before it Develops
New research suggests myeloma could be prevented before it develops out of symptomless condition in bone marrow.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!